0286.Hk
The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
Business. The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
The company's capital structure is characterized by a debt-to-equity ratio of 1.15, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 1.16, suggesting the company has sufficient short-term assets to cover its short-term liabilities. The price-to-book ratio of 0.34 indicates that the company's market value is significantly below its book value, which may reflect market skepticism about its future earnings potential.
Profitability metrics show a challenging financial position, with a negative return on equity of -24.05% and a negative return on assets of -9.05%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating margin is negative, with an operating loss of 110,306,000 HKD, and the net loss of 177,421,000 HKD further underscores the company's financial difficulties.
The company's revenue is primarily concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic fluctuations and regulatory changes. The absence of detailed segment reporting limits the ability to assess the performance of different parts of the business.
The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year. The outlook for the current fiscal year does not provide specific numeric deltas, but the company's financial performance suggests a need for significant operational improvements to achieve profitability. The capital expenditure of -36,369,000 HKD indicates ongoing investment in the business, which may be aimed at driving future growth.
Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure for additional share issuance. The company's financial structure and negative cash flow from operations pose a credit risk, which could affect its ability to secure financing on favorable terms.
Recent events include the disclosure of a net loss and a negative operating income, which are reflected in the company's financial statements. There are no recent filings or transcripts that provide additional insights into the company's strategic direction or operational performance.
- The company is currently unprofitable, with a net loss of 177,421,000 HKD and a negative return on equity of -24.05%.
- The company's liquidity position is medium, with a current ratio of 1.16 and a debt-to-equity ratio of 1.15.
- The company's revenue is concentrated in a single segment, increasing its exposure to regional economic and regulatory risks.
- The company's capital expenditure of -36,369,000 HKD suggests ongoing investment, but the financial performance indicates a need for significant operational improvements.
- The company's risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate pressure for additional share issuance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 0286.HK Market data — financials · 2026-05-26
- Aidigong Maternal & Child Health Ltd Market data — analyst estimates · 2026-05-26